Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 17,164 Shares of Boston Scientific Corporation $BSX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 328,295 shares of the medical equipment provider’s stock after selling 17,164 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Boston Scientific were worth $14,012,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of BSX. Renaissance Group LLC acquired a new stake in shares of Boston Scientific in the fourth quarter worth $28,064,000. PensionDanmark Pensionsforsikringsaktieselskab lifted its position in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Meiji Yasuda America Inc acquired a new stake in Boston Scientific during the 4th quarter worth about $4,708,000. Finally, Harvest Portfolios Group Inc. raised its stake in shares of Boston Scientific by 6.1% during the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after buying an additional 34,598 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 0.7%

BSX opened at $51.78 on Friday. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $46.00 and a 200 day moving average price of $59.40. The company has a market cap of $75.04 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Oppenheimer decreased their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Canaccord Genuity Group reduced their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Bank of America dropped their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.